The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
Background Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well....
Uloženo v:
| Vydáno v: | BMC neurology Ročník 19; číslo 1; s. 23 - 10 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
12.02.2019
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1471-2377, 1471-2377 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well.
Objectives/Aims: To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS).
Methods
We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures.
Results
Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (
p
= 0.01), fatigue (
p
< 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (
p
< 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (
p
≤ 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (
p
< 0.05) but not T2 hyperintense lesion volume (
p
> 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (
N
= 146) corroborated these results.
Conclusions
Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes. |
|---|---|
| AbstractList | Abstract Background Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well. Objectives/Aims: To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS). Methods We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures. Results Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p ≤ 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (N = 146) corroborated these results. Conclusions Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes. Background Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well. Objectives/Aims: To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS). Methods We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures. Results Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression ( p = 0.01), fatigue ( p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables ( p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status ( p ≤ 0.01 for both), and higher MLR correlated with increased whole-brain atrophy ( p < 0.05) but not T2 hyperintense lesion volume ( p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients ( N = 146) corroborated these results. Conclusions Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes. Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well. To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS). We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures. Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p ≤ 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (N = 146) corroborated these results. Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes. Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well. We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures. Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p [less than or equai to] 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (N = 146) corroborated these results. Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes. Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well.BACKGROUNDSerum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well.To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS).OBJECTIVES/AIMSTo characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS).We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures.METHODSWe identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures.Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p ≤ 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (N = 146) corroborated these results.RESULTSUnadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p ≤ 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (N = 146) corroborated these results.Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes.CONCLUSIONSElevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes. Background Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well. Objectives/Aims: To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS). Methods We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures. Results Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p [less than or equai to] 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (N = 146) corroborated these results. Conclusions Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes. Keywords: Multiple sclerosis, Neutrophil-to-Lympocyte ratio, Monocyte-to-Lympocyte ratio, Brain atrophy, MRI, Patient-reported outcomes Background Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of medicine; recent evidence shows correlation with psychological parameters as well. Objectives/Aims: To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR and MLR in persons with multiple sclerosis (MS). Methods We identified a large cohort of clinically well-defined patients from our longitudinal database that included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of 3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic regression model with repeated measures. Results Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p ≤ 0.01 for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset of untreated patients (N = 146) corroborated these results. Conclusions Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive immune processes (denominator), and consequently reflect a complementary and independent marker for severity of MS-related neurological disability and MRI outcomes. |
| ArticleNumber | 23 |
| Audience | Academic |
| Author | Glanz, Bonnie I. Hemond, Christopher C. Bakshi, Rohit Chitnis, Tanuja Healy, Brian C. |
| Author_xml | – sequence: 1 givenname: Christopher C. orcidid: 0000-0002-2408-4638 surname: Hemond fullname: Hemond, Christopher C. email: christopher.hemond@umassmed.edu organization: Department of Neurology, University of Massachusetts Medical Center, Department of Neurology, Harvard Medical School, Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham & Women’s Hospital – sequence: 2 givenname: Bonnie I. surname: Glanz fullname: Glanz, Bonnie I. organization: Department of Neurology, Harvard Medical School, Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham & Women’s Hospital – sequence: 3 givenname: Rohit surname: Bakshi fullname: Bakshi, Rohit organization: Department of Neurology, Harvard Medical School, Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham & Women’s Hospital, Department of Radiology, Harvard Medical School – sequence: 4 givenname: Tanuja surname: Chitnis fullname: Chitnis, Tanuja organization: Department of Neurology, Harvard Medical School, Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham & Women’s Hospital – sequence: 5 givenname: Brian C. surname: Healy fullname: Healy, Brian C. organization: Department of Neurology, Harvard Medical School, Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham & Women’s Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30755165$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstu1DAUhiNURC_wAGxQJDZsUuzEjp0NUlVxqVSJTVlbJ7Yz45FjD7YDytvwqDgzLe2MAEVKfPn_zznH_3lx4rzTRfEao0uMefs-4przpkK4q3BNaFU_K84wYbiqG8ZOnoxPi_MYNwhhxgl-UZw2iFGKW3pW_Lpb69LpKQW_XRtbJV_ZedyuvZyTLsGpcvRuNznaCpCMjyUEXRqn9Fbnl0t2LiFGLw0krcqfJq0XePDWr4wEWyoToTfWpHnH7gMYV8Lu8DlzynGyyWytLqO0Ovho4svi-QA26lf334vi26ePd9dfqtuvn2-ur24r2aImVYp2LUfAgQBmsmn7HpCkpJUDxooBIEJVtwwp7xRiepA90bzlTMtetrpuLoqbPVd52IhtMCOEWXgwYrfgw0pASCb_liAaej1gAqxDRPUIAANldUcR6jVXXWZ92LO2Uz9qJXNjAtgD6OGOM2ux8j9E2zBMGpYB7-4BwX-fdExiNFFqa8FpP0VRY05pizu6SN8eSTd-Ci63alE1hNZ11z6qVpALMG7w-Vy5QMUV5bhpCScL6_IvqvwoPRqZszeYvH5gePO00D8VPuQrC9heIPNlxqAHIU1akrPUbazASCxJFvski5xksSRZLPeBj5wP8P956r0nZq1b6fDYi3-bfgPD2Ami |
| CitedBy_id | crossref_primary_10_1016_j_msard_2023_104699 crossref_primary_10_1016_j_bbi_2021_11_022 crossref_primary_10_1177_11786469241284423 crossref_primary_10_3389_fimmu_2022_918064 crossref_primary_10_3389_fimmu_2024_1336862 crossref_primary_10_3390_ijerph18063318 crossref_primary_10_1016_j_jocn_2022_05_020 crossref_primary_10_1186_s12883_023_03101_0 crossref_primary_10_1016_j_bbi_2023_01_012 crossref_primary_10_1186_s41983_024_00802_2 crossref_primary_10_3892_etm_2021_9616 crossref_primary_10_3389_fimmu_2020_597858 crossref_primary_10_1093_cei_uxae115 crossref_primary_10_1136_bmjopen_2023_075398 crossref_primary_10_1016_j_psychres_2025_116604 crossref_primary_10_1007_s00421_021_04668_7 crossref_primary_10_1007_s10157_020_01975_9 crossref_primary_10_1038_s41467_021_23472_7 crossref_primary_10_1007_s00520_024_08700_2 crossref_primary_10_1055_a_2338_5397 crossref_primary_10_1007_s00415_020_10322_7 crossref_primary_10_1016_j_msard_2023_104570 crossref_primary_10_1007_s00415_021_10935_6 crossref_primary_10_1111_1744_9987_13753 crossref_primary_10_1016_j_jneuroim_2020_577307 crossref_primary_10_1038_s41467_025_59074_w crossref_primary_10_1155_2020_5483981 crossref_primary_10_1016_j_bbih_2024_100940 crossref_primary_10_1016_j_msard_2025_106446 crossref_primary_10_1016_j_msard_2022_103514 crossref_primary_10_3389_fimmu_2020_00594 crossref_primary_10_1186_s12883_023_03384_3 crossref_primary_10_1016_j_msard_2021_102921 crossref_primary_10_3389_fimmu_2025_1487814 crossref_primary_10_3390_ijms23084205 crossref_primary_10_1016_j_neurol_2021_05_004 crossref_primary_10_1038_s41598_025_10162_3 crossref_primary_10_1038_s41598_024_81225_0 crossref_primary_10_2147_JIR_S501150 crossref_primary_10_3390_jcm11144085 crossref_primary_10_1212_NXI_0000000000200278 crossref_primary_10_3389_fnins_2023_1305176 crossref_primary_10_1016_j_jocn_2022_05_002 crossref_primary_10_1016_j_msard_2020_102345 crossref_primary_10_3389_fimmu_2022_911779 crossref_primary_10_1016_j_ygeno_2023_110708 crossref_primary_10_1016_j_jneuroim_2022_577931 crossref_primary_10_1096_fj_202402492R crossref_primary_10_1038_s41598_023_41443_4 crossref_primary_10_1111_jnc_14930 crossref_primary_10_1038_s41598_023_33827_3 crossref_primary_10_1016_j_msard_2023_104796 crossref_primary_10_3389_fnins_2023_1285678 crossref_primary_10_3389_fimmu_2021_628024 crossref_primary_10_3390_brainsci14050423 crossref_primary_10_1016_j_nbd_2024_106744 crossref_primary_10_1016_j_jocn_2022_08_017 crossref_primary_10_1016_j_msard_2022_103507 crossref_primary_10_3389_fimmu_2023_1213532 crossref_primary_10_1016_j_pediatrneurol_2023_03_009 crossref_primary_10_1155_2022_3265029 crossref_primary_10_3390_cells8101114 crossref_primary_10_1038_s41598_021_01942_8 crossref_primary_10_1016_j_dscb_2025_100222 crossref_primary_10_3390_jcm13247820 crossref_primary_10_1016_j_ejpn_2024_04_011 crossref_primary_10_1016_j_immuni_2021_01_004 crossref_primary_10_1111_ane_13401 crossref_primary_10_1186_s12883_021_02432_0 crossref_primary_10_1007_s11481_025_10203_8 crossref_primary_10_1016_j_jocn_2022_10_017 crossref_primary_10_1016_j_exger_2022_111955 crossref_primary_10_1080_15321819_2023_2277806 crossref_primary_10_5472_marumj_1186732 crossref_primary_10_1177_1352458520951382 crossref_primary_10_24938_kutfd_1643896 crossref_primary_10_1002_hsr2_1004 crossref_primary_10_1080_17520363_2024_2441106 crossref_primary_10_1177_13524585241310764 crossref_primary_10_1177_10998004231215777 crossref_primary_10_1155_2024_5383099 crossref_primary_10_1177_1099800420924126 crossref_primary_10_3389_fimmu_2024_1325938 crossref_primary_10_2147_JIR_S548421 crossref_primary_10_1007_s42399_022_01383_y crossref_primary_10_1016_j_msard_2020_102084 crossref_primary_10_3389_fneur_2022_1051865 |
| Cites_doi | 10.1159/000341583 10.1159/000443835 10.1016/j.ctrv.2015.10.003 10.1586/14779072.2016.1154788 10.1038/nrn.2016.69 10.1002/jmri.10053 10.1186/s12943-017-0707-7 10.1161/STROKEAHA.116.013627 10.1212/NXI.0000000000000432 10.1002/ana.21640 10.1177/1352458518798590 10.1016/j.jcma.2015.08.010 10.1016/S0889-1591(03)00061-8 10.1016/j.msard.2017.10.009 10.1016/j.autrev.2006.02.012 10.1093/brain/awy069 10.1016/0277-9536(91)90150-B 10.1007/s10072-014-1976-1 10.4049/jimmunol.157.4.1638 10.1371/journal.pone.0122686 10.1016/j.jneuroim.2011.11.009 10.2165/00002018-200427100-00005 10.7224/1537-2073.2012-019 10.1002/ana.20703 10.1177/014662167700100306 10.1084/jem.20141015 10.1016/j.pnpbp.2018.03.012 10.7860/JCDR/2017/24388.9764 10.1016/j.ynstr.2015.12.004 10.3109/00207454.2015.1050492 10.1212/NXI.0000000000000123 10.1016/j.jstrokecerebrovasdis.2013.01.011 10.1111/psyg.12260 10.1212/01.wnl.0000210506.00078.5c 10.1016/S1474-4422(14)70305-9 10.1177/1352458507079657 10.1038/nrneurol.2016.110 10.1016/j.jns.2013.03.002 10.1097/00005650-199206000-00002 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12883-019-1245-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Neurosciences Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2377 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_4eabef14a7904db0aa1a5729500be8d9 PMC6371437 A581364847 30755165 10_1186_s12883_019_1245_2 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: American Academy of Neurology – fundername: ; |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV NPM 3V. 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-d59680a8a4a17c36bba0c546cf11d7aa045d911d7589d07efcb4e8687ecbc6e23 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 92 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000458733300005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2377 |
| IngestDate | Fri Oct 03 12:23:37 EDT 2025 Tue Nov 04 01:59:59 EST 2025 Fri Sep 05 07:33:52 EDT 2025 Thu Oct 09 21:51:27 EDT 2025 Tue Nov 11 10:07:56 EST 2025 Tue Nov 04 17:19:17 EST 2025 Thu Apr 03 07:10:09 EDT 2025 Tue Nov 18 22:53:31 EST 2025 Sat Nov 29 01:39:53 EST 2025 Sat Sep 06 07:35:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Neutrophil-to-Lympocyte ratio Multiple sclerosis Monocyte-to-Lympocyte ratio Patient-reported outcomes MRI Brain atrophy |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-d59680a8a4a17c36bba0c546cf11d7aa045d911d7589d07efcb4e8687ecbc6e23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-2408-4638 |
| OpenAccessLink | https://link.springer.com/10.1186/s12883-019-1245-2 |
| PMID | 30755165 |
| PQID | 2183452296 |
| PQPubID | 44772 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4eabef14a7904db0aa1a5729500be8d9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6371437 proquest_miscellaneous_2185561957 proquest_journals_2183452296 gale_infotracmisc_A581364847 gale_infotracacademiconefile_A581364847 pubmed_primary_30755165 crossref_citationtrail_10_1186_s12883_019_1245_2 crossref_primary_10_1186_s12883_019_1245_2 springer_journals_10_1186_s12883_019_1245_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-02-12 |
| PublicationDateYYYYMMDD | 2019-02-12 |
| PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-12 day: 12 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC neurology |
| PublicationTitleAbbrev | BMC Neurol |
| PublicationTitleAlternate | BMC Neurol |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | ME Afari (1245_CR5) 2016; 14 MG Frank (1245_CR17) 2016; 4 P Rieckmann (1245_CR33) 2004; 27 MG Mazza (1245_CR14) 2018; 84 JJ Ware (1245_CR28) 1992; 30 A Ocana (1245_CR3) 2017; 16 B Hemmer (1245_CR1) 2015; 14 MK Mishra (1245_CR37) 2016; 12 J Langelaar Van (1245_CR40) 2018; 141 1245_CR23 1245_CR22 I Guzel (1245_CR21) 2016; 79 F Al-Hussain (1245_CR13) 2017; 11 SA Gauthier (1245_CR24) 2006; 5 DKB Li (1245_CR38) 2006; 66 S Tokgoz (1245_CR7) 2013; 22 LS Radloff (1245_CR26) 1977; 1 M Nakhaei-Nejad (1245_CR31) 2018; 5 JM Rumble (1245_CR2) 2015; 212 S Lattanzi (1245_CR8) 2016; 47 C Bridel (1245_CR32) 2015; 2 T Kalelioglu (1245_CR10) 2017; 17 H Fu (1245_CR6) 2015; 61 Y Gidron (1245_CR34) 2003; 17 FS Dhabhar (1245_CR12) 1996; 157 M Naegele (1245_CR19) 2012; 242 KA Ribbons (1245_CR35) 2015; 10 TF Nishijima (1245_CR4) 2015; 41 ME Kuyumcu (1245_CR9) 2012; 34 S Kern (1245_CR16) 2008; 14 G Serfőző (1245_CR15) 2016; 23 X Wei (1245_CR30) 2002; 15 A Rostami (1245_CR39) 2013; 333 ES Wohleb (1245_CR18) 2016; 17 HL Weiner (1245_CR36) 2009; 65 SS Demirci (1245_CR20) 2016; 126 CD Sherbourne (1245_CR29) 1991; 32 E Akıl (1245_CR11) 2015; 36 CH Polman (1245_CR25) 2005; 58 RD Larson (1245_CR27) 2013; 15 |
| References_xml | – volume: 34 start-page: 69 year: 2012 ident: 1245_CR9 publication-title: Dement Geriatr Cogn Disord doi: 10.1159/000341583 – volume: 23 start-page: 67 year: 2016 ident: 1245_CR15 publication-title: Neuroimmunomodulation doi: 10.1159/000443835 – volume: 41 start-page: 971 year: 2015 ident: 1245_CR4 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2015.10.003 – volume: 14 start-page: 573 year: 2016 ident: 1245_CR5 publication-title: Expert Rev Cardiovasc Ther doi: 10.1586/14779072.2016.1154788 – volume: 17 start-page: 497 year: 2016 ident: 1245_CR18 publication-title: Nat Rev Neurosci doi: 10.1038/nrn.2016.69 – volume: 15 start-page: 203 year: 2002 ident: 1245_CR30 publication-title: J Magn Reson Imaging doi: 10.1002/jmri.10053 – volume: 16 start-page: 1 year: 2017 ident: 1245_CR3 publication-title: Mol Cancer doi: 10.1186/s12943-017-0707-7 – volume: 47 start-page: 1654 year: 2016 ident: 1245_CR8 publication-title: Stroke doi: 10.1161/STROKEAHA.116.013627 – volume: 5 start-page: e432 year: 2018 ident: 1245_CR31 publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000000432 – volume: 65 start-page: 239 year: 2009 ident: 1245_CR36 publication-title: Ann Neurol doi: 10.1002/ana.21640 – ident: 1245_CR23 doi: 10.1177/1352458518798590 – volume: 79 start-page: 54 year: 2016 ident: 1245_CR21 publication-title: J Chinese Med Assoc doi: 10.1016/j.jcma.2015.08.010 – volume: 17 start-page: 310 year: 2003 ident: 1245_CR34 publication-title: Brain Behav Immun doi: 10.1016/S0889-1591(03)00061-8 – ident: 1245_CR22 doi: 10.1016/j.msard.2017.10.009 – volume: 5 start-page: 532 year: 2006 ident: 1245_CR24 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2006.02.012 – volume: 141 start-page: 1334 year: 2018 ident: 1245_CR40 publication-title: Brain doi: 10.1093/brain/awy069 – volume: 32 start-page: 705 year: 1991 ident: 1245_CR29 publication-title: Soc Sci Med doi: 10.1016/0277-9536(91)90150-B – volume: 36 start-page: 423 year: 2015 ident: 1245_CR11 publication-title: Neurol Sci doi: 10.1007/s10072-014-1976-1 – volume: 157 start-page: 1638 year: 1996 ident: 1245_CR12 publication-title: J Immunol doi: 10.4049/jimmunol.157.4.1638 – volume: 10 start-page: 1 year: 2015 ident: 1245_CR35 publication-title: PLoS One doi: 10.1371/journal.pone.0122686 – volume: 242 start-page: 60 year: 2012 ident: 1245_CR19 publication-title: J Neuroimmunol doi: 10.1016/j.jneuroim.2011.11.009 – volume: 27 start-page: 745 year: 2004 ident: 1245_CR33 publication-title: Drug Saf doi: 10.2165/00002018-200427100-00005 – volume: 15 start-page: 15 year: 2013 ident: 1245_CR27 publication-title: Int J MS Care doi: 10.7224/1537-2073.2012-019 – volume: 58 start-page: 840 year: 2005 ident: 1245_CR25 publication-title: Ann Neurol doi: 10.1002/ana.20703 – volume: 1 start-page: 385 year: 1977 ident: 1245_CR26 publication-title: Appl Psychol Meas doi: 10.1177/014662167700100306 – volume: 212 start-page: 23 year: 2015 ident: 1245_CR2 publication-title: J Exp Med doi: 10.1084/jem.20141015 – volume: 84 start-page: 229 year: 2018 ident: 1245_CR14 publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2018.03.012 – volume: 11 start-page: CC01 year: 2017 ident: 1245_CR13 publication-title: J Clin Diagn Res doi: 10.7860/JCDR/2017/24388.9764 – volume: 4 start-page: 62 year: 2016 ident: 1245_CR17 publication-title: Neurobiol Stress doi: 10.1016/j.ynstr.2015.12.004 – volume: 126 start-page: 700 year: 2016 ident: 1245_CR20 publication-title: Int J Neurosci doi: 10.3109/00207454.2015.1050492 – volume: 2 start-page: e123 year: 2015 ident: 1245_CR32 publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000000123 – volume: 22 start-page: 1169 year: 2013 ident: 1245_CR7 publication-title: J Stroke Cerebrovasc Dis doi: 10.1016/j.jstrokecerebrovasdis.2013.01.011 – volume: 17 start-page: 506 year: 2017 ident: 1245_CR10 publication-title: Psychogeriatrics doi: 10.1111/psyg.12260 – volume: 66 start-page: 1384 year: 2006 ident: 1245_CR38 publication-title: Neurology doi: 10.1212/01.wnl.0000210506.00078.5c – volume: 14 start-page: 406 year: 2015 ident: 1245_CR1 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70305-9 – volume: 14 start-page: 6 year: 2008 ident: 1245_CR16 publication-title: Mult Scler doi: 10.1177/1352458507079657 – volume: 12 start-page: 539 year: 2016 ident: 1245_CR37 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2016.110 – volume: 333 start-page: 76 year: 2013 ident: 1245_CR39 publication-title: J Neurol Sci doi: 10.1016/j.jns.2013.03.002 – volume: 61 start-page: 269 year: 2015 ident: 1245_CR6 publication-title: Clin Lab – volume: 30 start-page: 473 year: 1992 ident: 1245_CR28 publication-title: Med Care doi: 10.1097/00005650-199206000-00002 |
| RelatedPersons | Yang, Cindy |
| RelatedPersons_xml | – fullname: Yang, Cindy |
| SSID | ssj0017841 |
| Score | 2.5105958 |
| Snippet | Background
Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of... Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of pathogenic... Background Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers of... Abstract Background Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte ratio (MLR) have been used as biomarkers... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 23 |
| SubjectTerms | Atrophy Biological markers Biomarkers Blood tests Brain atrophy Brain damage Brain research Cardiovascular disease Care and treatment Demyelinating diseases Development and progression Fatigue Immune system Immunology Inflammation Innate immunity Lymphocytes Magnetic resonance imaging Medical records Medicine Medicine & Public Health Monocyte-to-Lympocyte ratio Monocytes MRI Multiple sclerosis Nervous system Neurochemistry Neuroimaging Neurological complications Neurology Neurosurgery Neutrophil-to-Lympocyte ratio Neutrophils Patient-reported outcomes Patients Quality of life Ratios Research Article Sensitivity analysis Yang, Cindy |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yiHgRv62uEkEQlLLNa5Mmx1VcvLh4UNhbSNKULTza5bVvof-Nf6ozaVq3T9SLt7b5aJL5ZTLppL8h5I1QytSVqtOaWZcWwolUOeNTp4xUhWBecRuCTZTn5_LiQn29EeoLz4RN9MDTwJ0U3lhfs8KUKisqmxnDDAeLkGeZ9bIKv-5lpZo3U9F_gN606MNkUpz0DIPqwrYZqf8Lnm5Wq1Ag6_9dJd9Ykw7PSx44TcNadHaf3ItGJD2dGv-A3PLtQ3LnS3STPyI_QPi09fth111dNtt06NLtCGLr3Dh4atqKAvjCzUFSgENPzc7TZomPO2xHaqIUfUXxyy0NNJhRbdIq8vQOY6jbYtQJasLLR6iHzocWaQ-thfFo-sfk-9mnbx8_pzEUQ-pElg9pxZWQmZGmMKx0ubDWZI6DaGvGqtIYMAwrhZdcqiorfe1s4aWQpXfWCb_Jn5Cjtmv9M0Itq3lecG5zsH0AEcbWdelLZnMsVsuEZLNotIs85RguY6vDfkUKPUlTgzQ1SlNvEvJuKXI1kXT8LfMHlPeSEfm1wwNAnY6o0_9CXULeIlo0agFonDPxZwboIvJp6VMuWS4KWPoTcrzKCbPXrZNnvOmoPXqNZisy3SuRkNdLMpbEE3Gt7_YhD0Y2VRyqeDrBc-kS6G30f_KElCvgrvq8Tmmby8AtLpDBMYc6388Q_9WsPw7p8_8xpC_I3Q1O0BBs55gcDbu9f0luu-uh6XevwvT-CcBDWQg priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LjtMwFLVgQGg2vAcCAzISEhLImriJHXuFBsSIDSMWIHVn-RWmUpWUJh0pf8On4uu6GVLEbNi19SO-zvH147rnIPSaS6lrJ2tSU2NJyS0n0mpPrNRClpx6yUwUm6jOz8V8Lr-mA7cuXavc-cToqF1r4Yz8BKZyYP-W_P3qJwHVKIiuJgmNm-gWyGYDzqv5uOGiEFNLkUwq-ElHQVo3bJ5BAKBkZDaZiyJl_9-O-Y-Zaf_W5F7oNM5IZ_f-15b76G5ai-LTLXgeoBu-eYjufEnR9kfoV8AQbvymX7eri8WS9C1ZDuHtt3boPdaNw6Gi-GUvKaKqw3rt8WKU2e2XA9YJDN5hOADGkU0zeV_sEt1vP8S6DYhXYB0fPoR68O7uI-5Ca0OHLrrH6PvZp28fP5Ok6EAsz4ueOCa5yLXQpaaVLbgxOrcsIKSm1FVah_Wlk_CRCenyytfWlF5wUXlrLPez4ggdNG3jnyJsaM1CJzJThCVUAJY2dV35ipoCitUiQ_nu3Sqb6M5BdWOp4rZHcLWFgwpwUAAHNcvQ27HIasv1cV3mDwCYMSPQdMcf2vUPlUa9Kr02vqalrmReOpNrTTUL2xmW58YLJzP0BuCmwJmExlmd_hMRTARaLnXKBC14GVYQGTqe5AxOwE6Td0hTyQl16gpmGXo1JkNJuFjX-HYT84BAqmShiidbfI8mBfcPYVSWoWqC_InN05RmcREpyjkQQRahzne7MXLVrH926bPrjXiODmcwdqMazzE66Ncb_wLdtpf9olu_jCP_N0fYZks priority: 102 providerName: ProQuest |
| Title | The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis |
| URI | https://link.springer.com/article/10.1186/s12883-019-1245-2 https://www.ncbi.nlm.nih.gov/pubmed/30755165 https://www.proquest.com/docview/2183452296 https://www.proquest.com/docview/2185561957 https://pubmed.ncbi.nlm.nih.gov/PMC6371437 https://doaj.org/article/4eabef14a7904db0aa1a5729500be8d9 |
| Volume | 19 |
| WOSCitedRecordID | wos000458733300005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA66K-KL90t1HSIIglJsp02aPO7KLvqww7BeWJ9CkqbuwNAu044w_8af6jmZtNrxAvpS2sllkpMvJyc96XcIec6l1FUpq7hKjY1zbnksrXaxlVrInKdOMuODTRSzmTg_l_PwHXfbn3bvXZJeU_tpLfjrNsXAuLD1Rfr-nMWgd_dhtRMYr-Hs_afBdYCOtOC-_G2x0QLkefp_1cY_LUe7RyV3_KV-GTq59V8duE1uBquTHm5hcodccfVdcv00-NXvkW-AFlq7dbdqLi8Wy7hr4uUGxrmxm85RXZcU0OofdpI8flqqV44uhoC63XJDdRh2V1J81Us9b2bQs7QMxL7dxtdtMEwF1f7PN1AP7U850hZaC1JctPfJx5PjD2_exiF2Q2x5knVxySQXiRY612lhM26MTiwDLFRpWhZagyVZSrxlQpZJ4Sprcie4KJw1lrtp9oDs1U3tHhFq0oplOWMmA2MJIKRNVRWuSE2GxSoRkaQfUGUDsTnG11gqv8ERXG0lr0DyCiWvphF5ORS53LJ6_C3zEaJkyIiE3P6HZvVFhfmtcqeNq9JcFzLJS5NonWoGGxeWJMaJUkbkBWJModqAxlkdvn6ALiIBlzpkIs14DrZCRA5GOWG623Fyj1IV1E2r0M5FanzJI_JsSMaSeISuds3a58FQqJJBFQ-3oB66BIoeHaYsIsUI7qM-j1PqxYUnI-dI-ZhBna960P9o1h9F-vifcj8hN6Y4a3wYngOy163W7im5Zr92i3Y1IVeL88JfxYTsHx3P5mcT_2YFnubvTuefJ14_fAfQrWH0 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqgoAL78dCASOBkEBR403i2AeEyqNq1XbFoUi9Gdtx6EqrZNlkQfk3_AJ-IzPeJCWL6K0Hbrvrx47tb2Y8sTMfIc-5lDrPZB7kzNgg5pYH0moXWKmFjDlzMjGebCKdTMTJify0QX5178LgtcrOJnpDnZUWn5FvoyvH7N-Sv51_C5A1Ck9XOwqNFSwOXPMDQrbqzf4HWN8X4_Hux-P3e0HLKhBYHkZ1kCWSi1ALHWuW2ogbo0ObgJQ5Y1mqNexxMokfEyGzMHW5NbETXKTOGssdJjoAk38J7HiKwV560gd4DM_w2pNTJvh2xZDKF4J1JByIk2A88H2eIuBvR_CHJ1y_pbl2VOs94O6N_23ubpLr7V6b7qyU4xbZcMVtcuWovU1wh_wEHaGFW9aLcn46nQV1GcwaQHdpm9pRXWQUBPdf1oq81lRULxyd9jTC9ayhugW7yyg-4KY-W2jrXWjWpjOuG9-3QXIOqv2fN9AP7e520gqkhQWcVnfJ5wuZn3tksygL94BQw_IEFi0xEWwRQXG0yfPUpcxE2CwXIxJ2WFK2TeeOrCIz5cM6wdUKfgrgpxB-ajwir_om81Uuk_Mqv0OA9hUxDbn_oVx8Va1VU7HTxuUs1qkM48yEWjOdQLiWhKFxIpMj8hLhrdBYgnBWt-98wBAx7ZjaSQSLeAw7pBHZGtQEI2eHxR2yVWtkK3UG6xF51hdjS7w4WLhy6esgAaxMoIv7K33qhwTuDY-JkxFJB5o2GPOwpJie-hTsHBNdRtDn604nz8T655Q-PH8QT8nVveOjQ3W4Pzl4RK6N0W545qEtslkvlu4xuWy_19Nq8cRbHUq-XLSq_gYt0cSX |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bi9QwFA6yyuKLd9fqqhEEQSnbTJs0eVwvg6IOC17Yt5Bb3YGhHaYdYf6NP9WcNK12vYD41mlO0uT0y8nJnPQ7CD1mQqjKiiqtiDZpwQxLhVEuNUJxUTDiBNUh2US5WPDTU3ES85y2w2n3ISTZf9MALE11d7S2VT_FOTtqCSTJ9dtgoPIvaOpt8MUCztHDdv3D5zGMAEG1GMr8bbXJYhQ4-3-1zD8tTeePTZ6LnYYlaX71vwdzDV2J3ig-7uFzHV1w9Q20_z7G22-ibx5FuHbbbtOsz5artGvS1c6__8bsOodVbbFHcfhxrijgqsVq4_ByTLTbrXZYRTg4i-EvYBz4NKP9xTYS_na70LaG9BVYhYfvfDt4OP2IW99br9Flewt9mr_6-OJ1GnM6pIZleZdaKhjPFFeFIqXJmdYqM9RjpCLElkp5D9MKuKRc2Kx0ldGF44yXzmjD3Cy_jfbqpnZ3ENakonlBqc69E-WhpXRVla4kOodqFU9QNrxcaSLhOeTdWMmw8eFM9pqXXvMSNC9nCXo6Vln3bB9_E34OiBkFgag73Gg2X2Sc97JwSruKFKoUWWF1phRR1G9oaJZpx61I0BPAmwRz4jtnVPwqwg8RiLnkMeUkZ4X3IRJ0OJH0ZsBMiwfEymiGWgn-L1DmC5agR2Mx1ISjdbVrtkEGUqQK6ps46AE-DskvABBIpQkqJ9CfjHlaUi_PAkk5AyrI3Lf5bJgAP7r1R5Xe_Sfph2j_5OVcvnuzeHsPXZ7BBAqZeg7RXrfZuvvokvnaLdvNg2AUvgNQvWes |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+neutrophil-to-lymphocyte+and+monocyte-to-lymphocyte+ratios+are+independently+associated+with+neurological+disability+and+brain+atrophy+in+multiple+sclerosis&rft.jtitle=BMC+neurology&rft.au=Hemond%2C+Christopher+C&rft.au=Glanz%2C+Bonnie+I&rft.au=Bakshi%2C+Rohit&rft.au=Chitnis%2C+Tanuja&rft.date=2019-02-12&rft.eissn=1471-2377&rft.volume=19&rft.issue=1&rft.spage=23&rft_id=info:doi/10.1186%2Fs12883-019-1245-2&rft_id=info%3Apmid%2F30755165&rft.externalDocID=30755165 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon |